Amir H. Kashani, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.
Ophthalmology Times® talked with Mark Bullimore and discussed the control of myopia progression with low-concentration atropine from the Hong-Kong LAMP study at this year's ARVO meeting.
Ophthalmology Times® talked with T. Y. Alvin Liu, MD, about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.
In a presentation during the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held at the Ernest N. Morial Convention Center in New Orleans, Luxa Biotechnology offered details of a clinical trial evaluating transplantation of cells derived from adult retinal pigmented epithelium stem cells to treat dry AMD.
Adverum Biotechnologies Inc. shared nonclinical data at ARVO 2023 in New Orleans that staggered, bilateral administration of Ixo-vec in NHPs was well tolerated with encouraging therapeutic activity and no signals of increased inflammation.
The team of Japanese researchers found that the choroidal MBR in the nasal region is correlated with systemic arterial stiffness and is significantly lower in patients with coronary artery multivessel disease.
In a presentation at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans, data demonstrated the loss of retinal pigmented epithelial and photoreceptor cells, both of which are required for visual function.
According to data presented at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans, post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced geographic atrophy (GA) growth.
Dr Carl Danzig, MD, FASRS, spoke at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.
Dr Caroline Baumal talks about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.
Hydrogen-rich water may have a place in treatment of retinal degeneration. The team of investigators found that the hydrogen-rich water significantly improved the retinal blood flow (RBF) dysregulation in type 2 diabetic mice.
Hydrogen water intake improved retinal blood flow (RBF) dysregulation in response to flicker stimulation and systemic hyperoxia in type 2 diabetic mice.
Thomas V. Johnson, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on retinal engineering and RGC replacement.
Ophthalmology Times® talked with Caroline Baumal, MD, about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.
Ophthalmology Times® talked with Carl Danzig, MD, FASRS, at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.
Dr Deborah Ferrington talks about her ARVO presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.
Japanese investigators have found an ocular biomarker of cardiovascular diseases.
According to data presented at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, staggered administration of Ixo-vec in non-human primates showed peak aflibercept protein levels in the second eye within the targeted therapeutic range, supporting the potential for bilateral administration.
The results indicated that SB15 had similar efficacy, safety, immunogenicity, and pharmacokinetics compared to aflibercept out to week 56 of the phase III trial.
SB15 (Samsung Bioepis) has shown similar efficacy, pharmacokinetics, safety, immunogenicity to aflibercept after 56 Weeks in phase 3 clinical trial.
David Szanto, a medical student at Stony Brook, and working with the Department of Neurology at the Icahn School of Medicine at Mount Sinai, describes how an algorithm finds recurring patterns in the visual fields and the ganglion cell-inner plexiform layer thicknesses, and helps clinicians understand how prevalent those patterns are throughout the entire data.
Ophthalmology Times® talked with Deborah Ferrington, PhD, about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.
In a mouse model of glaucoma, defective calcium clearance was seen as a characteristic feature of early damage to the retinal ganglion cells (RGC).
Ophthalmology Times® talked with Roland Mattern, Director of Sales and Marketing for eSight and eSight User Gary Foster at this year's ARVO meeting about eSight Go, the new model of smart glasses for low vision enhancement
Ophthalmology Times® talked with George Magrath, MD, and Andrew Pucker, OD, MS, PhD, FAAO at this year's ARVO meeting about Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.
The Association for Research in Vision and Ophthalmology (ARVO) kicked off its annual meeting today at the Ernest N. Morial Convention Center in New Orleans.
Defective calcium clearance is a characteristic feature of early damage to the retinal ganglion cells (RGC) in a mouse model of glaucoma.
Patrick Yu-Wai-Man, MD, PhD, is being recognized by the ARVO Foundation for his research on gene replacement therapy for Leber hereditary optic neuropathy.
The Centre for Ocular Research and Education is demonstrating its latest discoveries for eye applications at the Association for Research in Vision and Ophthalmology’s annual meeting in New Orleans.
